9
Participants
Start Date
November 21, 2022
Primary Completion Date
October 28, 2024
Study Completion Date
October 28, 2024
Telisotuzumab Vedotin
Intravenous (IV) Infusion
Linkou Chang Gung Memorial Hospital /ID# 248145, Taoyuan
National Cheng Kung University Hospital /ID# 248142, Tainan City
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 248144, Kaohsiung City
Kaohsiung Chang Gung Memorial Hospital /ID# 248143, Kaohsiung City
Monash Medical Centre /ID# 247679, Clayton
Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 248329, Candiolo
Duplicate_Fondazione IRCCS San Gerardo dei Tintori /ID# 247584, Monza
Chungbuk National University Hospital /ID# 248405, Cheongju-si
Keimyung University Dongsan Hospital /ID# 247371, Daegu
Pusan National University Yangsan Hospital /ID# 248489, Yangsan
CHU Lille - Hôpital Albert Calmette /ID# 246263, Lille
Centre Jean Perrin /ID# 246268, Clermont-Ferrand
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267, Bron
Asklepios Fachkliniken Muenchen-Gauting /ID# 248082, Gauting
Hadassah Medical Center-Hebrew University /ID# 243298, Jerusalem
Rambam Health Care Campus /ID# 246781, Haifa
Meir Medical Center /ID# 243208, Kfar Saba
Rabin Medical Center /ID# 248631, Haifa
The Chaim Sheba Medical Center /ID# 243207, Ramat Gan
Cancer and Blood Speciality Clinic - Los Alamitos /ID# 251671, Los Alamitos
Valley Medical Center /ID# 251880, Renton
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 247585, Rome
National Cancer Center Hospital East /ID# 250317, Kashiwa-shi
Duplicate_National Hospital Organization Kyushu Cancer Center /ID# 250714, Fukuoka
Hokkaido University Hospital /ID# 250316, Sapporo
Osaka International Cancer Institute /ID# 251507, Osaka
Shizuoka Cancer Center /ID# 251752, Sunto-gun
National Cancer Center Hospital /ID# 250319, Chuo-ku
Samsung Medical Center /ID# 248407, Seoul
Lead Sponsor
AbbVie
INDUSTRY